News Beyond Our Pages

Hereditary angioedema (HAE) is characterized by recurrent and unpredictable angioedema attacks and occurs as a result of impairment of C1 esterase inhibitor activity, which leads to dysregulation of plasma kallikrein activity and excessive production of bradykinin. Banerji et al (JAMA 2018;320:2108-2; https://doi.org/10.1001/jama.2018.16773) assessed the efficacy of lanadelumab, an mAb that targets active plasma kallikrein, in the prevention of HAE attacks in a multicenter phase 3 trial. One hundred thirteen patients were randomized to receive one of 3 doses of subcutaneous lanadelumab or placebo over 26 weeks.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: News beyond our pages Source Type: research